<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03320915</url>
  </required_header>
  <id_info>
    <org_study_id>H-1702-040-830</org_study_id>
    <nct_id>NCT03320915</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT</brief_title>
  <official_title>Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Graft-versus-host-disease (GVHD) is common complication of hematopoietic stem cell
      transplantation. Vitamin D deficiency has been shown to be associated with increased risk of
      chronic GVHD in previous clinical studies. The purpose of this research is to investigate the
      effect of vitamin D supplementation in patients undergoing hematopoietic stem cell
      transplantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematopoietic stem cell transplant candidates are randomized to vitamin D supplementation or
      usual care. Five milligrams (200,000 IU) of cholecalciferol is injected to intervention group
      before stem cell transplantation. Additional supplementation of cholecalciferol during
      follow-up period is determined according to the level of 25(OH)D3. The primary outcome is the
      incidence of chronic GVHD which is determined according to IBMTR criteria. The secondary
      outcome consists of the incidence of acute GVHD, incidence and severity of vitamin D
      deficiency, and serum concentration of 25(OH)D3. Study investigators expect that
      supplementation of vitamin D may improve the outcome of stem cell transplantation by reducing
      the incidence of chronic GVHD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Events will be graded according to IBMTR criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute GVHD</measure>
    <time_frame>Up to 100 days</time_frame>
    <description>Events will be graded according to IBMTR criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D deficiency</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Severity and incidence of Vitamin D deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D3</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Serum concentration of 25(OH)D3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol 5mg (200,000 IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <other_name>Caldiferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with ≥ 18 years old

          -  Diagnosed with hematologic maligancies

          -  Planned to undergo allogeneic stem cell transplantation

        Exclusion Criteria:

          -  Hypercalcemia (ionized serum calcium level [iCa] &gt; 1.3 mmol/L, corrected serum calcium
             level &gt; 10.5 mg/dL)

          -  Impaired renal function (Serum creatinine ≥ 2.4 mg/dL)

          -  Not in complete remssion (except for myelodysplastic syndrome and myeloproliferative
             neoplasm)

          -  Consent withdrawal

          -  Considered inadequate under investigator's discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youngil Koh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae Hyun Kim</last_name>
    <phone>82-2-2072-0335</phone>
    <email>jaerung90@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youngil Koh, M.D.</last_name>
      <email>go01@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2017</study_first_submitted>
  <study_first_submitted_qc>October 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>October 22, 2017</last_update_submitted>
  <last_update_submitted_qc>October 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Youngil Koh</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

